A predictive index of biomarkers for ictogenesis from tier I safety pharmacology testing that may warrant tier II EEG studies

For purposes of this review, we have adopted the FDA term “sponsor” as it refers to any person who takes the responsibility for and initiates a nonclinical investigations of new molecular entities; FDA uses the term “sponsor” primarily in relation to investigational new drug application submissions.